Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders.
Neurocrine Biosciences stock last closed at $129.85, up 0.05% from the previous day, and has increased 16.46% in one year. It has overperformed other stocks in the Drug Manufacturers - Specialty & Generic industry by 0.46 percentage points. Neurocrine Biosciences stock is currently +54.16% from its 52-week low of $84.23, and -18.93% from its 52-week high of $160.18.
There are currently 100.36M NBIX shares outstanding. The market cap of NBIX is $13.03B. In the last 24 hours, 915,000 NBIX shares were traded.
You need an online brokerage account to access the NASDAQ market and buy NBIX shares.
Based on our research, eToro is the best place to buy stocks. Here's why:
Get $10 towards your purchase of stock by opening an account with eToro now. This offer is only for US users.
Open eToro AccountNow that you've picked your brokerage, the next step is to fill out some personal info so you are able to buy NBIX today.
Now that you've finished signing up on a good stock buying app, you need to deposit funds:
Watch the tutorial below to see the process of transferring money into your new investment account.
Once you have identified the best place to buy Neurocrine Biosciences stock, it's very important to evaluate their stock before you invest, so you actually understand the risk as well as the upside.
WallStreetZen was built to help part-time investors perform more in-depth fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on NBIX's stock page.
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge NBIX's intrinsic value.
Using relative valuations measures:
You can access more valuation analysis on NBIX's stock here.
Out of 17 Equities analysts who research NBIX, the consensus analyst rating on Neurocrine Biosciences is a Strong Buy
Please keep in mind that analyst ratings are not recommendations, nor are they investment advice.
Brian Abrahams, a top 15% analyst from RBC Capital maintains NBIX with a buy rating and lowers their NBIX price target from $180.00 to $177.00, on Feb 12, 2026.
Evan Seigerman, a top 25% analyst from BMO Capital maintains NBIX with a hold rating and lowers their NBIX price target from $147.00 to $140.00, on Feb 12, 2026.
Laura Chico, a top 5% analyst from Wedbush maintains NBIX with a buy rating and raises their NBIX price target from $149.00 to $151.00, on Feb 12, 2026.
Andrew S. Fein, a top 15% analyst from HC Wainwright & Co. maintains NBIX with a buy rating and lowers their NBIX price target from $198.00 to $192.00, on Feb 12, 2026.
Ami Fadia, a top 1% analyst from Needham maintains NBIX with a buy rating and lowers their NBIX price target from $187.00 to $185.00, on Feb 12, 2026.
Needham's Ami Fadia lowered their price target on Neurocrine Biosciences (NASDAQ: NBIX) by 1.1% from $187 to $185 on 2026/02/12. The analyst maintained their Buy rating on the stock.
Neurocrine Biosciences reported its Q4 and FY 2025 earnings.
Cutting their price target, Fadia spotlighted that management guided strong double-digit Ingrezza growth, in line with the $2.72B consensus, and expressed optimism regarding Crenessity's growth trajectory this year.
Looking ahead, the analyst said the company's pipeline is chock-a-block, with two Phase 3 programs currently underway and potential to deliver one new medicine every two years.
Neurocrine Biosciences reported:
For Q4 2025:
For FY 2025:
For FY 2026, management guided:
CEO Kyle W. Gano, Ph.D., commented: "Our 2025 performance reflects the strength and durability of our commercial business and meaningful progress we are making transforming Neurocrine into a broader, more diversified biopharmaceutical company.
"In 2026, we are focused on delivering strong, sustainable growth for INGREZZA and CRENESSITY® (crinecerfont) while advancing our pipeline anchored by Phase 3 programs, including osavampator in major depressive disorder and direclidine in schizophrenia.
"We expect this building momentum will create value for all stakeholders as Neurocrine is well positioned to improve the lives of even more patients in the years ahead."
You can dive deeper into what analysts are forecasting on the Neurocrine Biosciences stock forecast page.
Last year, NBIX earnings were $478.60M. Over the past 5 year, NBIX's earnings have gone up by 1.89% per year. This was slower than the Drug Manufacturers - Specialty & Generic industry average of 9.21%.
Last year, NBIX revenue was $2.86B. Over the last five year, NBIX's revenue has grown by 22.29% per year. This was faster than the Drug Manufacturers - Specialty & Generic industry average of 6.56%.
Dig into NBIX's earnings and revenue performance here.
In the past year, insiders at NBIX have sold more shares than they have bought.
Matt Abernethy, Chief Financial Officer of NBIX, was the latest NBIX insider to sell. They sold $150,185.20 worth of NBIX shares on Feb 13, 2026.
Dig into more about who owns NBIX stock here.
No, Neurocrine Biosciences doesn't provide an income stream by paying out dividends.
One of the biggest reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other community members have to say.
There are two primary order types:
Press the Open button and your broker will place the order.
If you require additional help with buying stocks on eToro, click the how to video below:
Now that you own some shares in NBIX, you'll want to keep up with your company.
Add NBIX to a watchlist to track the latest developments regarding your NBIX stock.
To summarize, here are the 6 steps to buy Neurocrine Biosciences stock:
If you need a online brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you want to get the latest news on your new investment in Neurocrine Biosciences, get started below.